The association of PIK3CA, AKT1, and mTOR with the overall survival of 106 AML patients (53 patients with high expression and 53 patients with low expression) is depicted in Fig. 2D–F through survival analysis using the GEPIA2 database. Here, PIK3CA is linked to acute myeloid leukemia.